Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Intangibles (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Intangibles for 12 consecutive years, with $20.0 million as the latest value for Q4 2025.

  • Quarterly Intangibles fell 19.31% to $20.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.0 million through Dec 2025, down 19.31% year-over-year, with the annual reading at $20.0 million for FY2025, 19.31% down from the prior year.
  • Intangibles hit $20.0 million in Q4 2025 for Coherus Oncology, up from $1.6 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $28.9 million in Q4 2023 to a low of $1.6 million in Q3 2025.
  • Historically, Intangibles has averaged $15.2 million across 5 years, with a median of $16.7 million in 2023.
  • Biggest five-year swings in Intangibles: surged 386.58% in 2023 and later crashed 94.46% in 2025.
  • Year by year, Intangibles stood at $3.6 million in 2021, then surged by 66.46% to $5.9 million in 2022, then skyrocketed by 386.58% to $28.9 million in 2023, then decreased by 14.11% to $24.8 million in 2024, then fell by 19.31% to $20.0 million in 2025.
  • Business Quant data shows Intangibles for CHRS at $20.0 million in Q4 2025, $1.6 million in Q3 2025, and $23.5 million in Q2 2025.